Trial intelligence / Profile preview

Neoadjuvant CAPOX followed by cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis

NL-OMON22353Phase 2Active, not recruiting

Sponsor
University Medical Center Groningen
Start
Apr 2013
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of capecitabine and oxaliplatin in colorectal cancer (CRC) and peritoneal carcinomatosis (PC), sponsored by University Medical Center Groningen. Primary endpoint: Complete cytoreduction rate. Started Apr 2013; status: active, not recruiting.

02

Drugs

capecitabineoxaliplatin
03

Conditions

colorectal cancer (CRC)peritoneal carcinomatosis (PC)

Beyond the preview

Go deeper on NL-OMON22353.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON22353.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call